In a significant leap forward for the field of biopharmaceutical development, Waters Corporation has unveiled a new software platform that is poised to revolutionize the way scientists characterize large, complex molecules. Dubbed HPLC CONNECT™, this innovative tool facilitates full digital connectivity between High-Performance Liquid Chromatography (HPLC) and Ultra-Performance Liquid Chromatography (UPLC) systems and Multi-Angle Light-Scattering (MALS) instruments from the Wyatt Technology™ portfolio.

The synapse of HPLC/UPLC systems with MALS marks a pivotal moment in the advancement of biologic drug discovery and development. In intricate disciplines such as the development of antibody-drug conjugates, complex protein conjugates, and gene therapies, precision and accuracy in molecular characterization are not just beneficial but essential. The HPLC CONNECT™ software emerges as a critical ally in this arena by streamlining processes, enhancing efficiency, and significantly boosting confidence in the analytical data produced.

Fraser McLeod, Vice President and General Manager of QA/QC and Wyatt Technology at Waters Corporation, emphasized the transformative impact of this software integration. According to McLeod, the software is designed to mitigate manual intervention – a potential source of errors – thereby ensuring a higher degree of reliability in data assessment which is crucial for the intricate process of biologic drug development.

Noteworthy is the software’s comprehensive approach, supporting a range of Waters™ LC systems including the ACQUITY™ Premier, Arc Premier, and Arc Systems. This inclusive support extends to control over various HPLC modules such as pumps, column ovens, UV detectors, and autosamplers, all accessible through a unified dashboard. This interface significantly simplifies the operational complexity often associated with these advanced scientific instruments, enabling scientists to focus more on their groundbreaking work and less on navigating technical complexities.

Additionally, Waters provides a specialized line of SEC columns, optimized for the separation of biomolecules by size, which stands as a testament to the company’s commitment to supporting the biopharmaceutical industry comprehensively. These columns are designed to deliver optimal performance in size-exclusion chromatography, an essential consideration for the purification and analysis of vital biotherapeutics such as monoclonal antibodies, proteins, peptides, and other biologics.

The global availability of the HPLC CONNECT™ software symbolizes an important stride towards enhancing the efficacy and precision of biopharmaceutical development processes. With its roots deeply embedded in over 65 years of expertise in chromatography, mass spectrometry, and thermal analysis, Waters Corporation continues to play a pivotal role in serving diversified scientific fields with innovative solutions. This latest development not only underscores the company’s dedication to the advancement of life sciences but also its ongoing commitment to fostering innovations that address the critical challenges faced by scientists today.